GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group by Kweekel, D M et al.
GSTP1 Ile105Val polymorphism correlates with progression-free
survival in MCRC patients treated with or without irinotecan:
a study of the Dutch Colorectal Cancer Group
DM Kweekel*,1, M Koopman
2, NF Antonini
3, T Van der Straaten
1, JWR Nortier
4, H Gelderblom
4, CJA Punt
2
and H-J Guchelaar
1
1Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands;
2Department of Oncology, University
Nijmegen Medical Center, Nijmegen, The Netherlands;
3Biometrics Department, Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands;
4Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
A Valine residue at position 105 of the GSTP1 protein results in decreased enzyme activity. As nuclear GSTP1 activity decreases
irinotecan cytotoxicity, Val-allele carriers may benefit more from irinotecan chemotherapy. Our aim was to investigate the association
of GSTP1 genotype with treatment outcome of irinotecan. Progression-free survival (PFS) and toxicity were determined in 267
metastatic colorectal cancer (MCRC) patients who were treated with first-line capecitabine (CAP) plus irinotecan (CAPIRI), or CAP
single agent in a prospective randomised phase III trial (CAIRO). GSTP1 genotype was determined by Pyrosequencing. Patients
receiving CAP showed a PFS of 6.6 (Ile/Ile), 6.0 (Ile/Val) and 6.5 months (Val/Val); compared to 7.0 (Ile/Ile), 8.8 (Ile/Val) and 9.2
months (Val/Val) with CAPIRI. Median PFS was 2.7 months longer in Val-allele carriers treated with CAPIRI compared to CAP
(P¼0.005). Patients with the Ile/Ile genotype showed similar PFS with CAPIRI and CAP (7.0 compared to 6.6 months, P¼0.972).
Toxicity did not differ significantly among genotypes. GSTP1 codon 105 polymorphism may be predictive for the response to
irinotecan-based chemotherapy in patients with MCRC, with the Val-allele being associated with a better outcome. Ile/Ile genotype
patients do not appear to benefit from the addition of irinotecan to CAP.
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The topo-isomerase I inhibitor irinotecan is an effective anti-
tumour agent that is frequently used in the treatment of patients
with metastatic colorectal cancer (MCRC) (Punt, 2004). Irinotecan
may lead to serious and potentially life-threatening side effects,
and not all patients respond to irinotecan. Therefore, pharmaco-
kinetic and pharmacogenomic studies are warranted to predict
which patients are most likely to benefit from irinotecan-based
chemotherapy (Pander et al, 2007).
The metabolic fate of irinotecan has been extensively studied.
Briefly, the (nearly) inactive prodrug irinotecan is metabolised to
SN-38 by the carboxylesterases in the liver. SN-38 is highly active
and inhibits topo-isomerase I, thereby interfering with DNA
replication and ultimately leading to cell death of dividing cells.
The active metabolite SN-38 is glucuronidated to the inactive
SN-38-G by uridine diphosphate glucuronosyl transferases (UGTs)
(Iyer et al, 1998). An alternative metabolic route leads to the
formation of APC (7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-
piperidino]-carbonyloxycamptothecin) by CYP3A4 and CYP3A5.
Differences in systemic exposure to irinotecan and SN-38 are to
some extent explained by genetic variations in UGT1A1 (Paoluzzi
et al, 2004) but not CYP3A (de Jong et al, 2006). Several membrane
efflux pumps have a function in the bio-distribution of irinotecan
and its metabolites, of which ABCB1 and ABCC2 are of particular
interest (de Jong et al, 2007; Kweekel et al, 2008). Much effort has
also been made to explore associations between polymorphisms in
UGTs and either toxicity or antitumour response of irinotecan.
Although there is evidence that a decreased glucuronidation
(UGT1A1*28 polymorphism) causes an increased risk of neutro-
penia and neutropenic fever (Mathijssen et al, 2003; Kweekel et al,
2008), data regarding the antitumour effects of irinotecan-based
chemotherapy are contradicting. This may be because of the fact
that systemic irinotecan levels are different from intratumoural
concentrations, and also because of differences in the capacity of a
tumour to metabolise or excrete the drug. An elevated expression
of UGTs or membrane pumps may prevent or limit irinotecan-
induced cell death in cancerous tissue, by causing a resistant
phenotype. In this respect, the intratumoural expression of a wide
range of proteins has been studied.
One of the proteins with an elevated expression in multidrug-
resistant cell lines is glutathione-S-transferase pi (GSTP1) (Tew,
1994). GSTP1 has multiple functions, of which the enzymatic
conjugation of glutathione (GSH) to xenobiotics is the most widely
known. Irinotecan or SN-38 are not known as substrates for this
conjugation reaction, but in vitro experiments show that if nuclear
expression of GSTP1 is decreased using a mushroom lectin,
colonic HCT8 cells are more sensitive to irinotecan (Goto et al,
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s2002). Therefore, GSTP1 may have an important function in the
clinical efficacy of irinotecan and/or its metabolites. In addition,
GSTP1 is a polymorphic gene, and the codon 105 polymorphism
(313A4G, or Ile105Val) influences the geometry of the hydro-
phobic-binding site of GSTP1 enzyme (Zimniak et al, 1994). This
results in differences in enzyme specificity and activity (Zimniak
et al, 1994; Watson et al, 1998), which may influence irinotecan
cytotoxicity. To our knowledge, the association between GSTP1
polymorphisms and clinical outcome in patients treated with
irinotecan has not yet been explored in detail. Therefore, the aim
of this study was to investigate the associations of GSTP1 Ile105Val
with progression-free survival (PFS) of MCRC patients treated with
irinotecan-containing chemotherapy.
PATIENTS AND METHODS
Subjects
Blood samples were obtained from patients enrolled in a multi-
center phase III trial, the CAIRO study of the Dutch Colorectal
Cancer Group (DCCG), of which the results have been published
recently (Koopman et al, 2007). We refer to this article for a
detailed description of eligibility criteria and response or toxicity
evaluation. In summary, patients with MCRC were allocated to
sequential (regimen A) or combination treatment (regimen B).
Regimen A consisted of first-line capecitabine (1250mgm
 2day
 1
b.i.d. on days 1–14, every 3 weeks: CAP), second-line irino-
tecan (350mgm
 2day
 1 on day 1 every 3 weeks) and third-line
CAP (1000mgm
 2day
 1 b.i.d. on days 1–14 every 3 weeks) plus
oxaliplatin (130mgm
 2 on day 1 every 3 weeks). Regimen B
consisted of first-line CAP (1000mgm
 2day
 1 b.i.d. on days
1–14, every 3 weeks) plus irinotecan (250mgm
 2day
 1 on day
1 every 3 weeks: CAPIRI), followed by second-line CAP plus
oxaliplatin (as described in regimen A).
Dose reductions were performed for CAP in case of grades
2–4 toxicity as described previously (Van Cutsem et al, 2001).
An initial irinotecan dose reduction to 80% in cycle 1 was
recommended in case of: age 470 years, WHO performance status
2 and/or serum bilirubin 1–1.5  upper normal limit. If well
tolerated, the dose was escalated to 100% in subsequent cycles. In
all patients, the irinotecan dose was reduced with 25% relative to
the previous cycle in case of any grades 3–4 toxicity with the
exception of nausea/vomiting without adequate prophylaxis. If
these toxicities recurred despite dose reduction, the dose was
reduced to 50% and upon next recurrence the treatment was
discontinued. Prophylactic use of haematological growth factors or
loperamide was not permitted. The accrual period was from
January 2003 to December 2004, and EDTA blood samples for
genotyping were collected from December 2003 to March 2005
after a protocol amendment. The objective of this amendment was
to perform genetic association studies regarding antitumour
response and toxicity. The study protocol and the amendment
were approved by the local ethical committees. Written informed
consent was obtained from all patients participating in the genetic
association study before blood collection. DNA was obtained from
267 patients (regimen B: 141 subjects; regimen A: 126). Tumour
evaluation was performed every three cycles according to the
RECIST criteria (Therasse et al, 2000), toxicity according to US
National Cancer Institute Common Toxicity Criteria, version 2.0.
All results were blinded with respect to genotype.
Genotyping
Genomic DNA was isolated from peripheral blood cells (Magna-
Pure Total Nucleic Acid Isolation Kit I on MagnaPure LC (Roche
Diagnostics, Mannheim, Germany)). Chromosomal DNA was
quantified using Nanodrop (Isogen, IJsselstein, The Netherlands)
and diluted to 10ngml
 1.
Primers for the GSTP1 Ile105Val polymorphism (rs1695) and
pyrosequence materials were obtained from Isogen Life Sciences
(IJsselstein, The Netherlands), Sepharose beads from Amersham
(Uppsala, Sweden). PCR reactions were performed using Hotstart
PCR mastermix (Qiagen, Hilden, Germany) on the MyCycler
(Biorad, Veenendaal, The Netherlands). Pyrosequence analysis was
performed on a Pyrosequencer 96MA (Biotage, Sweden). PCR
reactions were as follows: each reaction contained 10ng of DNA,
and 5pmol of each PCR primer (forward: 50-AGGACCTCCGCTGC
AAATAC-30, reverse 50-CTGGTGCAGATGCTCACATAGTT-30)i na
total of 12ml. Cycle conditions were as follows: initial denaturation
for 15min at 951C, 35 cycles of 951C 551C 721C each for 30s,
ended by 10min at 721C. The pyrosequence reactions were
performed according to the manufacturer’s protocol. The sequence
to analyse was A/GTCTCCCTCAT using the forward sequence
primer 50-CTCCGCTGCAAATAC-30.
Statistics
Possible associations of GSTP1 genotype with the incidence of
diarrhoea grades 3–4, febrile neutropenia and overall grades 3–4
toxicity according to the genotype were tested with a Fisher’s exact
test. The PFS was calculated from the date of randomisation to the
first observation of disease progression or death from any cause
reported after first-line treatment. The PFS curves were estimated
using the Kaplan–Meier method and compared using the log-rank
test. Multivariate analysis of PFS was performed by means of a Cox
proportional hazard model. All tests were two-sided and P-values
o0.05 were considered significant. All follow up data received
before March 2008 were included in this analysis, representing a
median follow up of 41 months. All analyses were performed using
SAS 9.1 and S-plus 6.2 software.
RESULTS
Patient characteristics are shown in Table 1. Patient ethnicity
was not recorded but the vast majority of patients were of
Caucasian descent. Genotyping the Ile105Val polymorphism was
successful in all 267 patients (100%). Overall genotype frequencies
for the GSTP1 Ile105Val polymorphism were as follows: Ile/Ile
107(40.3%), Ile/Val 129(48.1%) and Val/Val 31(11.6%). The geno-
type distribution was in Hardy–Weinberg equilibrium and the
allele frequencies (Ile 0.64, Val 0.36) were found in concordance
with HapMap data of Caucasian individuals published online
(http://www.ncbi.nlm.nih.gov/SNP/ snp_ref.cgi?rs¼1695).
Clinical efficacy
All 267 patients were evaluable for analysis of PFS: 126 patients
received first-line chemotherapy with CAP (regimen A), and 141
patients received first-line combination therapy with irinotecan
and CAP (CAPIRI, regimen B). For each separate genotype, we
compared PFS of patients receiving CAP with patients receiving
CAPIRI (Table 2, Figure 1). Overall, median PFS was longer for
patients receiving CAPIRI: 8.3 (95% confidence intervals (CI): 7.6–
8.8) months compared to 6.3 months (95% CI: 5.8–6.9, CAP). This
survival benefit from CAPIRI treatment was observed in patients
of the Ile/Val and Val/Val genotypes, but not in patients with the
Ile/Ile genotype. The median PFS for the separate genotypes
receiving CAP were as follows: 6.6 months (Ile/Ile, n¼43), 6.0
months (Ile/Val, n¼65) and 6.5 months (Val/Val, n¼18),
P¼0.886. In the CAPIRI regimen, median PFS were 7.0 months
(Ile/Ile, n¼64), 8.8 months (Ile/Val, n¼64) and 9.2 months (Val/
Val, n¼13), P¼0.078. Ile/Ile homozygotes receiving CAP had a
similar median PFS compared to Val-allele carriers (median 6.2
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smonths, P¼0.647). However, the Ile/Ile genotype receiving
CAPIRI had a significantly lower median PFS compared to the
other genotypes (median 7.0 months compared to 8.9 months,
P¼0.037). Multivariate Cox regression analysis reveals that PFS
for the Ile/Ile genotype is not significantly different depending on
the use of CAP or CAPIRI (P¼0.972), which is in contrast to Val-
allele carriers (P¼0.005). This result suggests that Ile/Ile
individuals do not benefit from the addition of irinotecan to CAP.
Toxicity
As was expected, the overall incidence of grades 3–4 diarrhoea and
febrile neutropenia was higher in patients treated with CAPIRI
(26.2%) compared to CAP (7.1%, Po0.001).
There were no statistically significant differences between
GSTP1 genotypes in the incidence of overall grades 3–4 toxicity
or grades 3–4 diarrhoea with CAP (Table 3).
Table 1 Patient characteristics
Characteristics CAP Ile/Ile, N¼43 (34%) Ile/Val, N¼65 (52%) Val/Val, N¼18 (14%) All patients, N¼126
Age (years)
Median 60 62 64 61.5
Range (36–78) (27–78) (47–78) (27–78)
470 8 (19%) 12 (19%) 3 (17%) 3 (17%)
Gender
Male (%) 27 (63%) 39 (60%) 10 (56%) 76 (60%)
WHO performance status (at start therapy)
0–1 41 (95%) 60 (93%) 18 (100%) 119 (94%)
2 2 (5%) 5 (8%) 0 7 (6%)
Prior adjuvant therapy 5 (12%) 6 (9%) 2 (11%) 13 (10%)
Predominant localisation of metastases (at inclusion)
Liver 27 (63%) 44 (68%) 12 (67%) 83 (66%)
Extrahepatic 15 (35%) 18 (28%) 6 (33%) 39 (31%)
Unknown 1 (2%) 3 (5%) — 4 (3%)
Site of primary
Colon and sigmoid 31 (72%) 42 (65%) 12 (67%) 85 (68%)
Rectum 11 (26%) 23 (35%) 6 (33%) 40 (32%)
Multiple tumours 1 (2%) — — 1 (o1%)
Serum LDH
Normal 32 (74%) 39 (60%) 11 (61%) 82 (65%)
XULN 11 (26%) 26 (40%) 7 (39%) 44 (35%)
Characteristics CAPIRI Ile/Ile, N¼64 (45%) Ile/Val, N¼64 (45%) Val/Val, N¼13 (10%) All patients, N¼141
Age (years)
Median 61.5 63 60 62
Range 41–81 37–78 45–72 37–81
470 12 (19%) 13 (20%) 1 (8%) 26 (18%)
Gender
Male (%) 38 (59%) 40 (63%) 9 (69%) 87 (62%)
WHO performance status (at start therapy)
0–1 59 (92%) 60 (94%) 13 (100%) 132 (94%)
2 5 (8%) 4 (6%) — 9 (6%)
Prior adjuvant therapy 10 (16%) 7 (11%) 1 (8%) 18 (13%)
Predominant localisation of metastases (at inclusion)
Liver 42 (66%) 46 (72%) 10 (77%) 98 (70%)
Extrahepatic 22 (34%) 18 (28%) 3 (23%) 43 (30%)
Site of primary
Colon and sigmoid 37 (58%) 41 (64%) 7 (54%) 85 (60%)
Rectum 27 (42%) 23 (36%) 6 (46%) 56 (40%)
Serum LDH
Normal 44 (69%) 39 (61%) 10 (77%) 93 (66%)
XULN 20 (31%) 25 (39%) 3 (23%) 48 (34%)
CAP¼capecitabine monotherapy; CAPIRI¼capecitabine plus irinotecan combination therapy.
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sDISCUSSION
This is the largest study to date that investigates a possible
association of the GSTP1 codon 105 polymorphism with response
and toxicity to irinotecan. We demonstrate that, as opposed
to the overall study population, Ile/Ile carriers do not benefit
from the addition of irinotecan to CAP. A number of studies have
been conducted to investigate the GSTP1 polymorphism with
respect to the treatment effects of other chemotherapeutic
compounds, such as busulfan (Zwaveling et al, 2008), melphalan
(Kuhne et al, 2008), cyclophosphamide (Zhong et al, 2006),
oxaliplatin (Stoehlmacher et al, 2002; Ruzzo et al, 2007) and
cisplatin (Goekkurt et al, 2006). In vitro data (Goto et al, 2002)
have shown that the presence of GSTP1 in the cell nucleus protects
the cell from irinotecan-induced apoptosis. As irinotecan or its
active metabolites are not known to be substrates of the GSTP1
enzyme, we hypothesise that GSH conjugation of reactive oxygen
species originating from irinotecan exposure may contribute to
this effect. The enzymatic activity of GSTP1 Val105 was found to
be lower compared to GSTP1 Ile105 (Watson et al, 1998), and
patients with Val/Val and Ile/Val may therefore benefit more
from irinotecan-induced oxidative damage, compared to the
Table 2 Progression-free survival of patients using CAP or CAPIRI, according to GSTP1 genotype
Genotype CAP PFS in months (95% CI) P-value CAPIRI PFS in months (95% CI) P-value
GSTP1
All genotypes (n¼267) 6.3 (5.8;6.9) — 8.3 (7.6;8.8) —
Ile/Ile (n¼107) 6.6 (5.5;8.3) Reference 7.0 (6.2;8.3) Reference
Ile/Val (n¼129) 6.0 (4.4;7.8) 0.697 8.8 (8.3;10.0) 0.025
Val/Val (n¼31) 6.5 (6.1;8.3) 0.661 9.2 (7.7;10.6) 0.696
Ile/Val+Val/Val (n¼160) 6.2 (5.4;7.9) 0.647 8.9 (8.3;9.9) 0.037
Ile/Ile vs Ile/Val vs Val/Val — 0.886 — 0.078
Ile/Ile Ile/Val+Val/Val All genotypes
Risk
Hazard ratio for PFS CAPIRI vs CAP 0.99 (0.67;1.48) 0.63 (0.46;0.87) 0.77 (0.56;0.93)
P-value 0.972 0.005 0.012
Median PFS, and P-values resulting from Cox regression analysis with serum LDH as a covariate. PFS¼progression-free survival; CAP¼single-agent capecitabine;
CAPIRI¼irinotecan combination therapy with capecitabine.
Table 3 Grades 3–4 toxicity with CAP and CAPIRI treatment
GSTP1-capecitabine single agent Ile\Ile, n¼43 Ile\Val, n¼65 Val\Val, n¼18 Total, n¼126 P-value
Overall grades 3–4 19 (44.2%) 29 (44.6%) 5 (27.8%) 53 (42.1%) P¼0.436
F
Diarrhoea grades 3–4 4 (9.3%) 4 (6.2%) 1 (5.6%) 9 (7.1%) P¼0.889
F
GSTP1-capecitabine plus irinotecan Ile\Ile, n¼64 Ile\Val, n¼64 Val\Val, n¼13 Total, n¼141 P-value
Overall grades 3–4 36 (56.3%) 37 (57.8%) 7 (53.8%) 80 (56.7%) P¼0.960
C
Diarrhoea grades 3–4 14 (21.9%) 18 (28.1%) 2 (15.4%) 34 (24.1%) P¼0.592
F
Febrile neutropenia grades 3–4 5 (7.8%) 3 (4.7%) 0 (0.0%) 8 (5.7%) P¼0.655
F
Diarrhoea grades 3–4 or febrile neutropenia 16 (25.0%) 19 (29.7%) 2 (15.4%) 37 (26.2%) P¼0.634
F
Values in this table describe worst grade toxicity, occurring during first-line capecitabine (single agent) or irinotecan plus capecitabine (combination) treatment. F¼Fisher’s exact
test; C¼w
2 test. In capecitabine single-agent users, no febrile neutropenia was recorded.
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Figure 1 Kaplan–Meier plot of progression-free survival (PFS). Solid lines: Ile/Ile, dotted lines: Ile/ValþVal/Val. If we compare median PFS of Ile/Ile
patients receiving CAP with those receiving CAPIRI, we see a nonsignificant difference (P¼0.972), whereas median PFS of Val carriers is significantly better
in the CAPIRI regimen (Po0.005). The full-colour version is available online.
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sIle/Ile genotype. Our findings now for the first time suggest a
possible relationship between the GSTP1 genotype and irinotecan
efficacy in cancer patients.
Based on the results of this study, one may question the use
of irinotecan in MCRC patients with the Ile/Ile genotype, as no
benefit in median PFS was observed while the incidence of
irinotecan-associated toxicity was unchanged.
A recent (FOCUS) study reports a multimarker analysis of,
among others, GSTP1 codon 105, in a large set of patients newly
presenting with MCRC (Braun et al, 2008). Patient characteristics
seem comparable with this study, but instead of CAP, 5-fluoro-
uracil (5-FU) was used. The GSTP1 genotype distribution in the
FOCUS study was different from this study (with a remarkable
43% of patients being of the homozygote mutant, GG, genotype).
Although the authors do not provide a detailed description of
GSTP1 associations with time to first-line treatment failure, it is
suggested that this genotype is not associated with differences in
response between 5-FU plus irinotecan treatment and 5-FU
alone. This finding is in contrast to the current results, but may
be related to the use of 5-FU instead of CAP (Seymour et al, 2007).
In addition, both studies report different toxicity patterns
and –incidence relating to irinotecan (Koopman et al, 2006).
The same unknown mechanisms underlying these differences may
also affect the association between GSTP1 genotypes and PFS.
A possible limitation to this study is the fact that samples were
obtained at a median of 5 months after inclusion, that is, most
patients who donated a sample were either in first- or second-line
therapy. The overall genotype distribution is not different from
data on Caucasians with colorectal carcinoma (Ile/Ile 47, Ile/Val 46
and Val/Val 6%) (Skjelbred et al, 2007). A similar distribution is
also found in CAPIRI patients, but not in those receiving CAP.
This may be a sign of selection bias; however, the genotype
distributions in both regimens are in Hardy–Weinberg equili-
brium, and the baseline characteristics of the patients randomised
to CAP do not differ significantly from the overall patient
characteristics of the complete cohort of the original study
(P40.2 for all characteristics, data not shown) (Koopman et al,
2007). In addition, a recent study found no association of GSTP1
genotype with overall survival or PFS in MCRC patients (Le
Morvan et al, 2007), indicating that GSTP1 is not a prognostic
marker. Therefore, selection bias seems unlikely.
In summary, the results of this study suggest that patients with
the Ile/Ile genotype do not benefit, in terms of PFS, from the
addition of irinotecan to CAP, in contrast to the Ile/Val and
Val/Val genotype. This is the first study reporting an association of
the GSTP1 codon 105 variants with the clinical efficacy of
irinotecan. If confirmed, this observation has important implica-
tions for the selection of MCRC patients who are eligible for
treatment with irinotecan.
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